002399.SZ

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | Cotação de Ações

Última atualização07/08/2025, 04:04:33

PreçoCN¥ 12,91

Variação (dia)-CN¥ 0,23 (-1.75%)▼

Min. 52 SemanasCN¥ 9,01

Máx. 52 SemanasCN¥ 14,34

Capitalização de mercado--

Endereço: No. 21 Langshan Road, Shenzhen, 518057

Telefone: 86 755 2698 0200

Funcionários: 1.926

SHENZHEN HEPALINK002399.SZ

CN¥ 12,91

- 0,231,8%

07/08/2025 04:04:33

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualCN¥ 12,91

Valor de mercado--

AberturaCN¥ 13,38

Preço máximoCN¥ 13,22

Preço mínimoCN¥ 12,83

VolumeCN¥ 6,3 mi

Fechamento anteriorCN¥ 13,14

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers finished dose pharmaceutical products, such as prolongin, inhixa, neoparin, and heparin and enoxaparin sodium injections; API products, including heparin and enoxaparin sodium APIs; and pancreatin API. It also provides molecule biologics CDMO services, which include research and development, manufacturing, quality management, and program management services, as well as technical support services. In addition, the company develops apabetalone (RVX-208), a BET bromodomain protein inhibitor in Phase 3 trial to reduce major adverse cardiovascular events, as well as in Phase 2 trial for diabetic nephropathy and fatty disease; oregovomab, a monoclonal antibody in Phase 3 trial for ovarian cancer, as well as in Phase 2 for pancreatic cancer; tosatoxumab (AR-301), a fully human IgG1 monoclonal antibody in Phase 3 trial for ventilator-associated pneumonia; AR20.5 in Phase 2 trial for pancreatic cancer; AR-101 in Phase 2 trial for ventilator-associated pneumonia; and H1710, a heparanase inhibitor preparation for solid tumors. Further, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

Ações relacionadas

Sichuan Kelun Pharmaceutical Co., Ltd.

002422.SZ ▼0.01% | CN¥ 28,13

Shenzhen Salubris Pharmaceuticals Co., Ltd.

002294.SZ ▼0.02% | CN¥ 29,84

Zhejiang NHU Company Ltd.

002001.SZ ▲0.02% | CN¥ 22,51

Jilin Aodong Pharmaceutical Group Co., Ltd.

000623.SZ ▲0.13% | CN¥ 16,63

Hualan Biological Engineering Inc.

002007.SZ ▲0.06% | CN¥ 15,81

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.

Busque ativos específicos e obtenha informações detalhadas sobre suas cotações

Utilize a função de busca para encontrar informações detalhadas sobre ativos específicos. Oferecemos dados precisos e atualizados, permitindo que você tome decisões informadas com base nas informações mais recentes do mercado.

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.